...
首页> 外文期刊>Cancer Cell International >A nomogram based on 9-lncRNAs signature for improving prognostic prediction of clear cell renal cell carcinoma
【24h】

A nomogram based on 9-lncRNAs signature for improving prognostic prediction of clear cell renal cell carcinoma

机译:基于9-lncRNAs特征的诺模图改善透明细胞肾细胞癌的预后预测

获取原文
           

摘要

Abnormal expressions of long noncoding RNAs (lncRNAs) are very common in clear cell renal cell carcinoma (ccRCC), and some of these have been reported to be highly correlated with prognosis of ccRCC patients. “edgeR” AND “DEseq” R packages were used to explore differentially expressed genes (DEGs) between normal and tumor tissues of ccRCC samples from The Cancer Genome Atlas (TCGA). Univariable Cox survival analysis, robust likelihood-based survival model and multivariable Cox regression analysis were used to identify prognostic lncRNAs and construct lncRNAs signature. Finally, a graphic nomogram based on the lncRNAs signature was developed to predict 1-, 3- and 5-year survival probability of ccRCC patients by using rms R package. 8413 DEGs including 2740 lncRNAs and 4530 mRNAs were identified between normal and tumor tissues. 395 lncRNAs were found to be associated with prognosis of ccRCC patients (P??0.05). Among these 395 prognostic lncRNAs, 9 key prognostic lncRNAs (RP13-463N16.6, CTD-2201E18.5, RP11-430G17.3, AC005785.2, RP11-2E11.9, TFAP2A-AS1, RP11-133F8.2, RP11-297L17.2 and RP11-348J24.2) were identified by using robust likelihood-based survival model. A 9-lncRNAs signature was constructed by using estimated regression coefficients of the 9 key prognostic lncRNAs. Results of χ2-test or Fisher’s exact test indicated that the 9-lncRNAs signature was significantly associated with clinicopathological characteristics such as tumor grade, T stage, N stage, M stage, TNM stage and survival outcome of ccRCC patients. Multivariate analysis showed that the 9-lncRNAs signature, age and M stage were independent prognostic factors. Finally, a graphic nomogram based on the lncRNAs signature, age and M stage was developed to predict 1-, 3- and 5-year survival probability of ccRCC patients by using rms R package. A 9-lncRNAs signature associated with prognosis of ccRCC patients was constructed and a promising prognostic nomogram based on the 9-lncRNAs signature was developed for 1-, 3- and 5-year OS prediction of ccRCC patients in this study.
机译:长的非编码RNA(lncRNA)的异常表达在透明细胞肾细胞癌(ccRCC)中非常普遍,据报道其中一些与ccRCC患者的预后高度相关。 “ edgeR”和“ DEseq” R软件包用于研究癌症基因组图谱(TCGA)的ccRCC样品的正常组织与肿瘤组织之间的差异表达基因(DEG)。使用单变量Cox生存分析,鲁棒的基于可能性的生存模型和多变量Cox回归分析来鉴定预后的lncRNA,并构建lncRNA的特征。最后,开发了基于lncRNAs签名的图形列线图,以通过使用rms R软件包预测ccRCC患者的1、3和5年生存率。在正常和肿瘤组织之间鉴定出8413个DEG,包括2740个lncRNA和4530个mRNA。发现395个lncRNA与ccRCC患者的预后有关(P 0.05)。在这395个预后的lncRNA中,有9个主要的预后lncRNA(RP13-463N16.6,CTD-2201E18.5,RP11-430G17.3,AC005785.2,RP11-2E11.9,TFAP2A-AS1,RP11-133F8.2,RP11 -297L17.2和RP11-348J24.2)是通过使用基于鲁棒似然性的生存模型确定的。通过使用9个主要预后性lncRNA的估计回归系数构建9-lncRNAs签名。 χ2检验或Fisher精确检验的结果表明,9-lncRNAs签名与ccRCC患者的临床病理特征(例如肿瘤分级,T期,N期,M期,TNM期和生存结果)显着相关。多因素分析表明9-lncRNAs的特征,年龄和M分期是独立的预后因素。最后,开发了基于lncRNAs签名,年龄和M期的图形列线图,以使用rms R软件包预测ccRCC患者的1、3和5年生存率。构建了与ccRCC患者预后相关的9-lncRNAs签名,并在此研究中开发了基于9-lncRNAs签名的有希望的预后诺模图,用于ccRCC患者的1年,3年和5年OS预测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号